MB
TRVI icon

MPM BioImpact’s Trevi Therapeutics TRVI Stock Holding History

MPM BioImpact’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.4M Buy
3,298,430
+11,343
+0.3% +$127K 3.04% 10
2025
Q4 		$41.2M Sell
3,287,087
-119,868
-4% -$1.39M 4.71% 4
2025
Q3 		$31.2M Hold
3,406,955
– – 5.1% 4
2025
Q2 		$18.6M Sell
3,406,955
-21,411
-0.6% -$133K 3.23% 9
2025
Q1 		$21.6M Buy
3,428,366
+333,470
+11% +$1.59M 3.71% 8
2024
Q4 		$12.8M Buy
3,094,896
+1,556,379
+101% +$4.98M 1.81% 25
2024
Q3 		$5.14M Buy
1,538,517
+28,343
+2% +$84.3K 0.77% 34
2024
Q2 		$4.5M Buy
1,510,174
+169,214
+13% +$470K 0.7% 42
2024
Q1 		$4.63M Buy
+1,340,960
New +$2.99M 0.74% 36

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return